Lista de obras - Annie Luetkemeyer - Dominio Público Uruguay

12 Weeks of Daclatasvir in Combination With Sofosbuvir for HIV-HCV Coinfection (ALLY-2 Study): Efficacy and Safety by HIV Combination Antiretroviral Regimens

artículo científico publicado en 2016

A pilot metabolomics study of tuberculosis immune reconstitution inflammatory syndrome

artículo científico publicado en 2019

A survey of tuberculosis infection control practices at the NIH/NIAID/DAIDS-supported clinical trial sites in low and middle income countries

artículo científico publicado en 2016

A172 C-EDGE CO-STAR: RISK OF REINFECTION FOLLOWING SUCCESSFUL THERAPY WITH ELBASVIR (EBR) AND GRAZOPREVIR (GZR) IN PERSONS WHO INJECT DRUGS (PWID) RECEIVING OPIOD AGONIST THERAPY (OAT)

Addition of nitazoxanide to PEG-IFN and ribavirin to improve HCV treatment response in HIV-1 and HCV genotype 1 coinfected persons naïve to HCV therapy: results of the ACTG A5269 trial

artículo científico publicado en 2013

Antiretroviral therapy and TB.

artículo científico publicado en 2006

Association of Rapid Molecular Testing With Duration of Respiratory Isolation for Patients With Possible Tuberculosis in a US Hospital

artículo científico publicado en 2018

Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19

scientific article published on 11 December 2020

Bartonella quintana Aortitis in a Man with AIDS, Diagnosed by Needle Biopsy and 16S rRNA Gene Amplification

artículo científico publicado en 2015

CDC/NIH Workshop. Tuberculosis biomarker and surrogate endpoint research roadmap

artículo científico publicado en 2011

CROI 2013: Complications of HIV disease, viral hepatitis, and antiretroviral therapy ⬇️

artículo científico publicado el 1 de abril de 2013

CROI 2014: Viral hepatitis and complications of HIV disease and antiretroviral therapy

artículo científico publicado en 2014

CROI 2015: Highlights of Viral Hepatitis Therapy

artículo científico publicado en 2015

CROI 2016: Viral Hepatitis and Liver Fibrosis.

artículo científico publicado en 2016

CROI 2017: Highlights of Advances in Viral Hepatitis and Liver Fibrosis

artículo científico publicado en 2017

CROI 2018: Highlights of Viral Hepatitis

artículo científico publicado en 2018

CROI 2019: highlights of viral hepatitis

artículo científico publicado en 2019

Clinical presentation and course of acute hepatitis C infection in HIV-infected patients

artículo científico publicado en 2006

Combined effect of CYP2B6 and NAT2 genotype on plasma efavirenz exposure during rifampin-based antituberculosis therapy in the STRIDE study

artículo científico publicado en 2015

Comparison of an interferon-gamma release assay with tuberculin skin testing in HIV-infected individuals

artículo científico publicado en 2007

Complications of HIV disease and antiretroviral therapy

artículo científico publicado en 2012

Complications of HIV disease and antiretroviral therapy.

artículo científico publicado en 2011

Complications of HIV disease and antiretroviral treatment.

artículo científico publicado en 2010

Current issues in the diagnosis and management of tuberculosis and HIV coinfection in the United States

artículo científico publicado el 1 de octubre de 2010

Daclatasvir plus Sofosbuvir for HCV in Patients Coinfected with HIV-1.

artículo científico publicado en 2015

Direct-acting antiviral treatment for HIV/HCV patients in safety net settings: patient and provider preferences

scientific article published on 04 March 2019

Disabling Dactylitis and Tenosynovitis Due to Mycobacterium haemophilum in a Patient With Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome

artículo científico publicado en 2017

Doxycycline Prophylaxis for Bacterial Sexually Transmitted Infections

scientific article published on 01 March 2020

Efficacy and Safety of Glecaprevir/Pibrentasvir in Patients Co-infected with Hepatitis C Virus and Human Immunodeficiency Virus-1: the EXPEDITION-2 Study.

artículo científico publicado en 2018

Elbasvir-Grazoprevir to Treat Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy: A Randomized Trial.

artículo científico publicado en 2016

Evaluation of Xpert MTB/RIF Versus AFB Smear and Culture to Identify Pulmonary Tuberculosis in Patients With Suspected Tuberculosis From Low and Higher Prevalence Settings

artículo científico publicado en 2016

Evaluation of two line probe assays for rapid detection of Mycobacterium tuberculosis, tuberculosis (TB) drug resistance, and non-TB Mycobacteria in HIV-infected individuals with suspected TB.

artículo científico publicado en 2014

Grazoprevir, Ruzasvir, and Uprifosbuvir for HCV After NS5A Treatment Failure

artículo científico publicado en 2017

HCV treatment barriers among HIV/HCV co-infected patients in the US: a qualitative study to understand low uptake among marginalized populations in the DAA era

scientific article published on 01 December 2019

HIV-associated central nervous system tuberculosis

artículo científico

Household ventilation and tuberculosis transmission in Kampala, Uganda ⬇️

artículo científico publicado el 1 de junio de 2013

Impact of Larger Sputum Volume on Xpert® MTB/RIF Assay Detection of Mycobacterium tuberculosis in Smear-Negative Individuals with Suspected Tuberculosis

artículo científico publicado en 2017

Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1.

artículo científico publicado en 2015

Ledipasvir/sofosbuvir for treatment of hepatitis C virus in sofosbuvir-experienced, NS5A treatment-naïve patients: Findings from two randomized trials

artículo científico publicado en 2017

Localized US Efforts to Eliminate Hepatitis C

artículo científico publicado en 2018

Phase I safety, pharmacokinetics, and pharmacogenetics study of the antituberculosis drug PA-824 with concomitant lopinavir-ritonavir, efavirenz, or rifampin

artículo científico publicado en 2014

Pilot study of pioglitazone before HCV retreatment in HIV/HCV genotype 1-infected subjects with insulin resistance and previous nonresponse to peginterferon and ribavirin therapy: A5239.

artículo científico publicado en 2014

Relationship Between Weight, Efavirenz Exposure, and Virologic Suppression in HIV-Infected Patients on Rifampin-Based Tuberculosis Treatment in the AIDS Clinical Trials Group A5221 STRIDE Study ⬇️

artículo científico publicado el 16 de abril de 2013

Resistance patterns and response to entecavir intensification among HIV-HBV-coinfected adults with persistent HBV viremia

artículo científico publicado en 2011

Retrospective-Prospective Study of Safety and Efficacy of Sofosbuvir based Direct Acting Antivirals in HIV/HCV Coinfected Participants with Decompensated Liver Disease Pre or Post Liver Transplant

artículo científico publicado en 2020

Role of a clinical pharmacist as part of a multidisciplinary care team in the treatment of HCV in patients living with HIV/HCV coinfection

article

Safety and Efficacy of Ombitasvir, Paritaprevir With Ritonavir ± Dasabuvir With or Without Ribavirin in Patients With Human Immunodeficiency Virus-1 and Hepatitis C Virus Genotype 1 or Genotype 4 Coinfection: TURQUOISE-I Part 2.

artículo científico publicado en 2017

Safety and Efficacy of Pegylated Interferon Lambda, Ribavirin, and Daclatasvir in HCV and HIV-Coinfected Patients

artículo científico publicado en 2017

Significant variation in presentation of pulmonary tuberculosis across a high resolution of CD4 strata ⬇️

artículo científico publicado el 1 de octubre de 2010

Sofosbuvir and Velpatasvir for the Treatment of HCV in Patients Coinfected with HIV-1: an Open-Label, Phase 3 Study

artículo científico publicado en 2017

Sofosbuvir and ribavirin for hepatitis C in patients with HIV coinfection

artículo científico publicado en 2014

Switching to bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with HIV

artículo científico publicado en 2020

The Safety and Immunogenicity of an Interleukin-12-Enhanced Multiantigen DNA Vaccine Delivered by Electroporation for the Treatment of HIV-1 Infection

artículo científico publicado en 2016

Timing of antiretroviral therapy for HIV-1 infection and tuberculosis

artículo científico publicado en 2011

Tuberculosis Infection in Early Childhood and the Association with HIV-exposure in HIV-uninfected Children in Rural Uganda

artículo científico publicado en 2016

Tuberculosis Therapy Modifies the Cytokine Profile, Maturation State, and Expression of Inhibitory Molecules on Mycobacterium tuberculosis-Specific CD4+ T-Cells

artículo científico publicado en 2016

Tuberculosis as part of the natural history of HIV infection in developing countries

artículo científico publicado en 2010

Tuberculosis drug development: ensuring people living with HIV are not left behind

artículo científico publicado en 2011

Tuberculosis immune reconstitution inflammatory syndrome in A5221 STRIDE: timing, severity, and implications for HIV-TB programs

artículo científico publicado en 2014

Understanding Hepatitis C Virus Drug Resistance: Clinical Implications for Current and Future Regimens

artículo científico publicado en 2017

Willing and able? Provision of medication for abortion by future internists.

artículo científico publicado en 2005

Lista de obras de Annie Luetkemeyer

12 Weeks of Daclatasvir in Combination With Sofosbuvir for HIV-HCV Coinfection (ALLY-2 Study): Efficacy and Safety by HIV Combination Antiretroviral Regimens

A pilot metabolomics study of tuberculosis immune reconstitution inflammatory syndrome

A survey of tuberculosis infection control practices at the NIH/NIAID/DAIDS-supported clinical trial sites in low and middle income countries

A172 C-EDGE CO-STAR: RISK OF REINFECTION FOLLOWING SUCCESSFUL THERAPY WITH ELBASVIR (EBR) AND GRAZOPREVIR (GZR) IN PERSONS WHO INJECT DRUGS (PWID) RECEIVING OPIOD AGONIST THERAPY (OAT)

Addition of nitazoxanide to PEG-IFN and ribavirin to improve HCV treatment response in HIV-1 and HCV genotype 1 coinfected persons naïve to HCV therapy: results of the ACTG A5269 trial

Antiretroviral therapy and TB.

Association of Rapid Molecular Testing With Duration of Respiratory Isolation for Patients With Possible Tuberculosis in a US Hospital

Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19

Bartonella quintana Aortitis in a Man with AIDS, Diagnosed by Needle Biopsy and 16S rRNA Gene Amplification

CDC/NIH Workshop. Tuberculosis biomarker and surrogate endpoint research roadmap

CROI 2013: Complications of HIV disease, viral hepatitis, and antiretroviral therapy ⬇️

CROI 2014: Viral hepatitis and complications of HIV disease and antiretroviral therapy

CROI 2015: Highlights of Viral Hepatitis Therapy

CROI 2016: Viral Hepatitis and Liver Fibrosis.

CROI 2017: Highlights of Advances in Viral Hepatitis and Liver Fibrosis

CROI 2018: Highlights of Viral Hepatitis

CROI 2019: highlights of viral hepatitis

Clinical presentation and course of acute hepatitis C infection in HIV-infected patients

Combined effect of CYP2B6 and NAT2 genotype on plasma efavirenz exposure during rifampin-based antituberculosis therapy in the STRIDE study

Comparison of an interferon-gamma release assay with tuberculin skin testing in HIV-infected individuals

Complications of HIV disease and antiretroviral therapy

Complications of HIV disease and antiretroviral therapy.

Complications of HIV disease and antiretroviral treatment.

Current issues in the diagnosis and management of tuberculosis and HIV coinfection in the United States

Daclatasvir plus Sofosbuvir for HCV in Patients Coinfected with HIV-1.

Direct-acting antiviral treatment for HIV/HCV patients in safety net settings: patient and provider preferences

Disabling Dactylitis and Tenosynovitis Due to Mycobacterium haemophilum in a Patient With Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome

Doxycycline Prophylaxis for Bacterial Sexually Transmitted Infections

Efficacy and Safety of Glecaprevir/Pibrentasvir in Patients Co-infected with Hepatitis C Virus and Human Immunodeficiency Virus-1: the EXPEDITION-2 Study.

Elbasvir-Grazoprevir to Treat Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy: A Randomized Trial.

Evaluation of Xpert MTB/RIF Versus AFB Smear and Culture to Identify Pulmonary Tuberculosis in Patients With Suspected Tuberculosis From Low and Higher Prevalence Settings

Evaluation of two line probe assays for rapid detection of Mycobacterium tuberculosis, tuberculosis (TB) drug resistance, and non-TB Mycobacteria in HIV-infected individuals with suspected TB.

Grazoprevir, Ruzasvir, and Uprifosbuvir for HCV After NS5A Treatment Failure

HCV treatment barriers among HIV/HCV co-infected patients in the US: a qualitative study to understand low uptake among marginalized populations in the DAA era

HIV-associated central nervous system tuberculosis

Household ventilation and tuberculosis transmission in Kampala, Uganda ⬇️

Impact of Larger Sputum Volume on Xpert® MTB/RIF Assay Detection of Mycobacterium tuberculosis in Smear-Negative Individuals with Suspected Tuberculosis

Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1.

Ledipasvir/sofosbuvir for treatment of hepatitis C virus in sofosbuvir-experienced, NS5A treatment-naïve patients: Findings from two randomized trials

Localized US Efforts to Eliminate Hepatitis C

Phase I safety, pharmacokinetics, and pharmacogenetics study of the antituberculosis drug PA-824 with concomitant lopinavir-ritonavir, efavirenz, or rifampin

Pilot study of pioglitazone before HCV retreatment in HIV/HCV genotype 1-infected subjects with insulin resistance and previous nonresponse to peginterferon and ribavirin therapy: A5239.

Relationship Between Weight, Efavirenz Exposure, and Virologic Suppression in HIV-Infected Patients on Rifampin-Based Tuberculosis Treatment in the AIDS Clinical Trials Group A5221 STRIDE Study ⬇️

Resistance patterns and response to entecavir intensification among HIV-HBV-coinfected adults with persistent HBV viremia

Retrospective-Prospective Study of Safety and Efficacy of Sofosbuvir based Direct Acting Antivirals in HIV/HCV Coinfected Participants with Decompensated Liver Disease Pre or Post Liver Transplant

Role of a clinical pharmacist as part of a multidisciplinary care team in the treatment of HCV in patients living with HIV/HCV coinfection

Safety and Efficacy of Ombitasvir, Paritaprevir With Ritonavir ± Dasabuvir With or Without Ribavirin in Patients With Human Immunodeficiency Virus-1 and Hepatitis C Virus Genotype 1 or Genotype 4 Coinfection: TURQUOISE-I Part 2.

Safety and Efficacy of Pegylated Interferon Lambda, Ribavirin, and Daclatasvir in HCV and HIV-Coinfected Patients

Significant variation in presentation of pulmonary tuberculosis across a high resolution of CD4 strata ⬇️

Sofosbuvir and Velpatasvir for the Treatment of HCV in Patients Coinfected with HIV-1: an Open-Label, Phase 3 Study

Sofosbuvir and ribavirin for hepatitis C in patients with HIV coinfection

Switching to bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with HIV

The Safety and Immunogenicity of an Interleukin-12-Enhanced Multiantigen DNA Vaccine Delivered by Electroporation for the Treatment of HIV-1 Infection

Timing of antiretroviral therapy for HIV-1 infection and tuberculosis

Tuberculosis Infection in Early Childhood and the Association with HIV-exposure in HIV-uninfected Children in Rural Uganda

Tuberculosis Therapy Modifies the Cytokine Profile, Maturation State, and Expression of Inhibitory Molecules on Mycobacterium tuberculosis-Specific CD4+ T-Cells

Tuberculosis as part of the natural history of HIV infection in developing countries

Tuberculosis drug development: ensuring people living with HIV are not left behind

Tuberculosis immune reconstitution inflammatory syndrome in A5221 STRIDE: timing, severity, and implications for HIV-TB programs

Understanding Hepatitis C Virus Drug Resistance: Clinical Implications for Current and Future Regimens

Willing and able? Provision of medication for abortion by future internists.